Featured updates to the NCCN guidelines

Robert J. Motzer; Eric Jonasch; M. Dror Michaelson; Lakshminarayanan Nandagopal; John L. Gore; Saby George; Ajjai Alva; Naomi Haas; Michael R. Harrison; Elizabeth R. Plimack; Jeffrey Sosman; Neeraj Agarwal; Sam Bhayani; Toni K. Choueiri; Brian A. Costello; Ithaar H. Derweesh; Thomas H. Gallagher; Steven L. Hancock; Christos Kyriakopoulos; Chad LaGrange; Elaine T. Lam; Clayton Lau; Bryan Lewis; Brandon Manley; Brittany McCreery; Andrew McDonald; Amir Mortazavi; Phillip M. Pierorazio; Lee Ponsky; Bruce G. Redman; Bradley Somer; Geoffrey Wile; Mary A. Dwyer; Lydia J. Hammond; Griselda Zuccarino-Catania

doi:10.6004/jnccn.2019.0054

Featured updates to the NCCN guidelines

Robert J. Motzer, Eric Jonasch, M. Dror Michaelson, Lakshminarayanan Nandagopal, John L. Gore, Saby George, Ajjai Alva, Naomi Haas, Michael R. Harrison, Elizabeth R. Plimack, Jeffrey Sosman, Neeraj Agarwal, Sam Bhayani, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Thomas H. Gallagher, Steven L. Hancock, Christos Kyriakopoulos, Chad LaGrangeElaine T. Lam, Clayton Lau, Bryan Lewis, Brandon Manley, Brittany McCreery, Andrew McDonald, Amir Mortazavi, Phillip M. Pierorazio, Lee Ponsky, Bruce G. Redman, Bradley Somer, Geoffrey Wile, Mary A. Dwyer, Lydia J. Hammond, Griselda Zuccarino-Catania

School of Medicine

Research output: Contribution to journal › Review article › peer-review

66 Scopus citations

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.

Original language	English (US)
Pages (from-to)	1278-1285
Number of pages	8
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2019.0054
State	Published - 2019

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2019.0054

Cite this

Motzer, R. J., Jonasch, E., Dror Michaelson, M., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., Sosman, J., Agarwal, N., Bhayani, S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Gallagher, T. H., Hancock, S. L., Kyriakopoulos, C., ... Zuccarino-Catania, G. (2019). Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 17(11), 1278-1285. https://doi.org/10.6004/jnccn.2019.0054

Motzer, RJ, Jonasch, E, Dror Michaelson, M, Nandagopal, L, Gore, JL, George, S, Alva, A, Haas, N, Harrison, MR, Plimack, ER, Sosman, J, Agarwal, N, Bhayani, S, Choueiri, TK, Costello, BA, Derweesh, IH, Gallagher, TH, Hancock, SL, Kyriakopoulos, C, LaGrange, C, Lam, ET, Lau, C, Lewis, B, Manley, B, McCreery, B, McDonald, A, Mortazavi, A, Pierorazio, PM, Ponsky, L, Redman, BG, Somer, B, Wile, G, Dwyer, MA, Hammond, LJ & Zuccarino-Catania, G 2019, 'Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 11, pp. 1278-1285. https://doi.org/10.6004/jnccn.2019.0054

@article{462d554152ec450f8b5b0db430b83f5c,

title = "Featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.",

author = "Motzer, {Robert J.} and Eric Jonasch and {Dror Michaelson}, M. and Lakshminarayanan Nandagopal and Gore, {John L.} and Saby George and Ajjai Alva and Naomi Haas and Harrison, {Michael R.} and Plimack, {Elizabeth R.} and Jeffrey Sosman and Neeraj Agarwal and Sam Bhayani and Choueiri, {Toni K.} and Costello, {Brian A.} and Derweesh, {Ithaar H.} and Gallagher, {Thomas H.} and Hancock, {Steven L.} and Christos Kyriakopoulos and Chad LaGrange and Lam, {Elaine T.} and Clayton Lau and Bryan Lewis and Brandon Manley and Brittany McCreery and Andrew McDonald and Amir Mortazavi and Pierorazio, {Phillip M.} and Lee Ponsky and Redman, {Bruce G.} and Bradley Somer and Geoffrey Wile and Dwyer, {Mary A.} and Hammond, {Lydia J.} and Griselda Zuccarino-Catania",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs. Funding Information: John L. Gore, MD, MS, Panel Member, has disclosed that he receives grant/research support from Ferring Pharmaceuticals, Inc. Saby George, MD, Panel Member, has disclosed that he receives grant/research support from Agensys Inc.; Astellas Pharma US, Inc.; Bayer Healthcare; Bristol-Myers Squibb Company; Eisai Inc.; Immunomedics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Seattle Genetics, Inc. He also receives consulting fees from Bristol-Myers Squibb Company, EMD Serano, Exelixis Inc., and Pfizer Inc. Ajjai Alva, MBBS, Panel Member, has disclosed that he receives grant/research support from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Bristol-Myers Squibb Company, Clovis Oncology, Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Esanik, Ionis, Progfenics, and Prometheus; and that he receives consulting fees from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Merck & Co., Inc., and Progfenics. Naomi Haas, MD, Panel Member, has disclosed that she was a scientific advisor for Pfizer Inc., and Roche Laboratories, Inc. Michael R. Harrison, MD, Panel Member, has disclosed that he receives honoraria from Bayer HealthCare; receives grant/research support from Bristol-Myers Squibb Company, Exelixis Inc., Merck & Co., Inc., and Pfizer Inc.; receives consulting fees from Exelixis Inc., Genentech, Inc., and Janssen Pharmaceutica Products, LP; and is a scientific advisor for Fujifilm Corporation and Exelixis Inc. Elizabeth R. Plimack, MD, MS, Panel Member, has disclosed that she receives grant/research support from Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Peloton Therapeutics, Inc., and Pfizer Inc.; and is a scientific advisor for and receives consulting fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Flatiron Health, Inc., Janssen Pharmaceutica Products, LP, Pfizer Inc., and Seattle Genetics, Inc. Jeffrey Sosman, MD, Panel Member, has disclosed that he receives consulting fees from Genentech, Inc., and is a scientific advisor for and receives honoraria from Bristol-Myers Squibb Company. Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships. Lydia J. Hammond, MBA, Guidelines Layout Specialist, NCCN, has disclosed that she has no relevant financial relationships. Griselda Zuccarino-Catania, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc. To view all of the conflicts of interest for the NCCN Guidelines panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx. Funding Information: In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Publisher Copyright: {\textcopyright} 2019. All rights reserved.",

year = "2019",

doi = "10.6004/jnccn.2019.0054",

language = "English (US)",

volume = "17",

pages = "1278--1285",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "11",

}

TY - JOUR

T1 - Featured updates to the NCCN guidelines

AU - Motzer, Robert J.

AU - Jonasch, Eric

AU - Dror Michaelson, M.

AU - Nandagopal, Lakshminarayanan

AU - Gore, John L.

AU - George, Saby

AU - Alva, Ajjai

AU - Haas, Naomi

AU - Harrison, Michael R.

AU - Plimack, Elizabeth R.

AU - Sosman, Jeffrey

AU - Agarwal, Neeraj

AU - Bhayani, Sam

AU - Choueiri, Toni K.

AU - Costello, Brian A.

AU - Derweesh, Ithaar H.

AU - Gallagher, Thomas H.

AU - Hancock, Steven L.

AU - Kyriakopoulos, Christos

AU - LaGrange, Chad

AU - Lam, Elaine T.

AU - Lau, Clayton

AU - Lewis, Bryan

AU - Manley, Brandon

AU - McCreery, Brittany

AU - McDonald, Andrew

AU - Mortazavi, Amir

AU - Pierorazio, Phillip M.

AU - Ponsky, Lee

AU - Redman, Bruce G.

AU - Somer, Bradley

AU - Wile, Geoffrey

AU - Dwyer, Mary A.

AU - Hammond, Lydia J.

AU - Zuccarino-Catania, Griselda

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs. Funding Information: John L. Gore, MD, MS, Panel Member, has disclosed that he receives grant/research support from Ferring Pharmaceuticals, Inc. Saby George, MD, Panel Member, has disclosed that he receives grant/research support from Agensys Inc.; Astellas Pharma US, Inc.; Bayer Healthcare; Bristol-Myers Squibb Company; Eisai Inc.; Immunomedics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Seattle Genetics, Inc. He also receives consulting fees from Bristol-Myers Squibb Company, EMD Serano, Exelixis Inc., and Pfizer Inc. Ajjai Alva, MBBS, Panel Member, has disclosed that he receives grant/research support from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Bristol-Myers Squibb Company, Clovis Oncology, Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Esanik, Ionis, Progfenics, and Prometheus; and that he receives consulting fees from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Merck & Co., Inc., and Progfenics. Naomi Haas, MD, Panel Member, has disclosed that she was a scientific advisor for Pfizer Inc., and Roche Laboratories, Inc. Michael R. Harrison, MD, Panel Member, has disclosed that he receives honoraria from Bayer HealthCare; receives grant/research support from Bristol-Myers Squibb Company, Exelixis Inc., Merck & Co., Inc., and Pfizer Inc.; receives consulting fees from Exelixis Inc., Genentech, Inc., and Janssen Pharmaceutica Products, LP; and is a scientific advisor for Fujifilm Corporation and Exelixis Inc. Elizabeth R. Plimack, MD, MS, Panel Member, has disclosed that she receives grant/research support from Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Peloton Therapeutics, Inc., and Pfizer Inc.; and is a scientific advisor for and receives consulting fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Flatiron Health, Inc., Janssen Pharmaceutica Products, LP, Pfizer Inc., and Seattle Genetics, Inc. Jeffrey Sosman, MD, Panel Member, has disclosed that he receives consulting fees from Genentech, Inc., and is a scientific advisor for and receives honoraria from Bristol-Myers Squibb Company. Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships. Lydia J. Hammond, MBA, Guidelines Layout Specialist, NCCN, has disclosed that she has no relevant financial relationships. Griselda Zuccarino-Catania, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc. To view all of the conflicts of interest for the NCCN Guidelines panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx. Funding Information: In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Publisher Copyright: © 2019. All rights reserved.

PY - 2019

Y1 - 2019

N2 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.

AB - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85075500785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075500785&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0054

DO - 10.6004/jnccn.2019.0054

M3 - Review article

C2 - 31693980

AN - SCOPUS:85075500785

SN - 1540-1405

VL - 17

SP - 1278

EP - 1285

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

Featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this